A cytogenetically cryptic (12;21) translocation is the most common molecular abnormality identi®ed in childhood acute lymphoblastic leukemia (ALL), and it generates a chimeric TEL-AML1 protein. Fusion of the Helix-Loop-Helix (HLH) (also called the pointed) domain of TEL to AML1 has been suggested to convert AML1 from a transcriptional activator to a repressor. To de®ne the structural features of this chimeric protein required for repression, we analysed the transcriptional activity of a series of TEL-AML1 mutants on the AML1-responsive interleukin-3 (IL-3) promoter, a potentially relevant gene target. Our results demonstrate that TEL-AML1 represses basal IL-3 promoter activity in lymphoid cells, and deletion mutant analysis identi®ed three distinct domains of TEL-AML1 that are required for repression; the HLH (pointed) motif contained in the TEL portion of TEL-AML1, and both the runt homology domain (Rhd) and the 74 amino acids downstream of the Rhd that are present in the AML1 portion of the fusion protein. Although AML1B (and a shorter AML1 isoform, AML1A) have transcriptional activating activity on the IL-3 promoter, fusion of the AML1 gene to the TEL gene generates a repressor of IL-3 expression. Consistent with this activity, freshly isolated human ALL cells that contain TEL-AML1 do not express IL-3.
Introduction
The TEL gene, which encodes a member of the ETS family of transcription factors, is involved in a variety of recurring chromosomal translocations. Although originally identi®ed by its fusion to the plateletderived growth factor receptor b (PDGFR-b) gene in chronic myelomonocytic leukemia accompanied by the t(5;12) (Golub et al., 1994) , the TEL gene (also called ETV6) has also been found fused to the MN1 gene , the ABL gene (Papadopoulos et al., 1995) , the JAK2 gene (Peeters et al., 1997a) , the EVI-1 gene (Peeters et al., 1997b) and the AML1 gene (Golub et al., 1995; Romana et al., 1995a) . The most common of these fusions is TEL-AML1, which is encoded by a t(12;21) translocation and is found in up to 25% cases of childhood B-lineage acute lymphoblastic leukemia (ALL) (Romana et al., 1995b; Shurtle et al., 1995) , but only rarely in adult ALL (Aguiar et al., 1996; Raynaud et al., 1996; Shih et al., 1996) .
The TEL fusion partner in this latter translocation, AML1, was ®rst identi®ed through its involvement in the t(8;21) translocation seen in acute myeloid leukemia with FAB-M2 morphology (Erickson et al., 1992; Miyoshi et al., 1991) . The t(8;21) translocation generates an AML1/ETO fusion protein whereas the heterodimeric partner of AML1, CBFb, is involved in the inv(16) abnormality, which generates a CBFb-MYH11 fusion product (Liu et al., 1993) . AML1 (also called CBFA2) and CBFb play essential roles in hematopoietic development; homozygous disruption of either gene in mice, using targeted homologous recombination, results in absent fetal liver hematopoiesis, extensive CNS hemorrhage and death on postcoital day (dpc) 12.5 (Okuda et al., 1996; Wang et al., 1996a,b; Sasaki et al., 1996) . At least three isoforms of human AML1 proteins have been identi®ed, AML1 (also called AML1A), AML1b, and AML1c (also called AML1B). AML1b and AML1c contain a context dependent transcriptional activating domain, that is not found in AML1A. This domain has recently been shown to bind the p300 co-activator molecule (Kitabayashi et al., 1998) . The AML1/ETO fusion protein has been shown to repress the promoter of several genes (e.g. TCRb, GM-CSF, IL-3) (Frank et al., 1995; Meyers et al., 1995; Uchida et al., 1997) and activate the promoter of other genes (e.g. BCL-2, M-CSFR) (Klampfer et al., 1996; Rhoades et al., 1996) . Similarly, the TEL-AML1 fusion protein has been shown to repress T-cell receptor b enhancer activity , but have no eect by itself on M-CSF receptor promoter activity (Fears et al., 1997) .
One potentially important class of target genes aected by AML1 fusion proteins are the hematopoietic growth factor genes (Frank et al., 1995; Uchida et al., 1997; Zent et al., 1996) . The interleukin-3 (IL-3) gene contains an AML1 consensus binding site in its promoter (located between nucleotides 7138 and 7133 relative to the transcriptional start site), which is required for its activation by the 479 amino acid isoform of AML1, AML1B, and by the shorter 250 amino acid isoform of AML1, AML1A (Uchida et al., 1997) . IL-3 is normally produced by activated T-cells, NK cells, mast cell lines, and megakaryocytes, but not by B cells, and it has broad eects on immature and mature hematopoietic cells (reviewed in Nimer and . Several IL-3 dependent murine B cell lines exist (Kinashi et al., 1988) , but IL-3 production by B cells has been found only in t(5;14) B cell ALL, where the IL-3 promoter is brought under the control of the immunoglobulin heavy chain enhancer, resulting in IL-3 production and presumed autocrine growth (Grimaldi and Meeker, 1989, 1990) . Given the proliferative and survival eects of IL-3 on B-lymphoblast cell growth (Tadmori et al., 1989 , Xia et al., 1992 , and the presence of an AML1 consensus binding site in the human IL-3 promoter, we investigated whether TEL-AML1 has regulatory eects on IL-3 promoter activity and whether IL-3 expression could be detected in ALL cells that contain the TEL-AML1 fusion product.
Our results demonstrate that TEL-AML1 functions as a transcriptional repressor of IL-3 promoter activity in transient transfection assays; this activity requires the HLH domain of TEL, the DNA binding and protein dimerization Rhd of AML1, and a 74 amino acid region of AML1 located downstream of the Rhd, which is not required for DNA binding. Deletion mutant analysis also addressed the function of several other domains in AML1, including the nuclear matrix targeting signal (NMTS) (Zeng et al., 1997) , the transcriptional activating domain (TAD), the ALYbinding region (Bruhn et al., 1997) , and the region containing two serine residues that can be phosphorylated by ERK kinase (Tanaka et al., 1996) . We used a sensitive reverse transcription polymerase chain reaction (RT ± PCR) assay to detect IL-3 mRNA, and found no evidence for autocrine production of IL-3 in TEL-AML1 positive ALL, a result consistent with our in vitro studies.
Results
TEL-AML1 protein can bind to the AML1 consensus binding site in the human IL-3 promoter AML1 proteins bind to a consensus DNA binding sequence, TGT/cGGT, via the runt homology domain (Meyers et al., 1993 , which is retained in the TEL-AML1 fusion protein. Having demonstrated that AML1B, AML1A, and AML1/ETO bind to the TGTGGT sequence in the human IL-3 promoter (Uchida et al., 1997) , we examined whether TEL-AML1 and several TEL-AML1 deletion mutant proteins (depicted in Figure 1 ) could also bind to these sequences using complementary oligonucleotides that contain the IL-3 5'¯anking sequences extending from 7160 to 7145 in an EMSA. Bacterially expressed wildtype TEL-AML1 protein speci®cally binds to the IL-3 promoter sequences, although less well than AML1A or AML1B (see Figure 2a) . A speci®c DNA-protein complex was generated by each of these proteins (lanes 3 ± 5, indicated by the arrow), which could be completely eliminated by adding a 100-fold molar excess of unlabeled self competitor (lane 6), or a competitor oligonucleotide which contains the TGTGGT sequence from the GM-CSF promoter (data not shown). A 100-fold molar excess of a mutant IL-3 promoter oligonucleotide (or a mutant GM-CSF promoter oligonucleotide) which lacks an intact TGTGGT sequence, failed to compete (lane 7, and data not shown), demonstrating the sequence speci®city of the binding. The TEL-AML1DHLH deletion mutant protein also bound to the wild type IL-3 oligonucleotide (lane 8), whereas lysate from bacteria transformed with the empty pET-30b(+) plasmid generated no gel shift complex (lane 2). As has been seen with other promoter elements, and other fusion proteins, the fusion of AML1 with TEL apparently reduces its binding anity for the TGTGGT DNA sequence in vitro.
Repression of the IL-3 promoter by TEL-AML1 requires the HLH domain in TEL, and two additional domains in AML1
We next performed transient co-transfection assays in MLA 144 T cells, which are capable of expressing IL-3, to de®ne the regulatory eect of TEL-AML1 on the transcriptional activity of the human IL-3 promoter. As we have previously shown (Uchida et al., 1997) , AML1B stimulated the promoter activity of the 7173 pCAT reporter plasmid (5.3-fold, as shown in Figure 3a ). In contrast, TEL-AML1 repressed the activity of these constructs by 60%. TEL-AML1DHLH, which lacks *90% of the amino acids in the HLH domain of TEL, does not function as a repressor, although it can bind DNA. In fact, TEL-AML1DHLH activated the 7173 pCAT plasmid *2.8-fold ( Figure 3a ) and deletion mutant analysis shows that this activation requires AML1 amino acids 216 ± 290, but not amino acids 290 ± 479 (data not shown). Thus, the HLH (or pointed) dimerization domain found in TEL-AML1 converts a potent transactivator into a transcriptional repressor of both the IL-3 promoter and the TCRa enhancer , as tested in lymphoid cells and non-lymphoid cells, respectively. To determine whether the consensus AML1 binding site in the IL-3 promoter was required for transcriptional repression by TEL-AML1, or transcriptional activation by AML1B, we utilized the 7173 mut pCAT reporter construct (described in Uchida et al., 1997) . The basal activity of this plasmid was only 30% of the wild type 7173 pCAT plasmid, which was too low to allow an assessment of the repressor activity of TEL-AML1. The TEL-AML1(290) mutant protein had equal or possibly slightly greater repressor activity on the wild type promoter than TEL-AML1 (Figure 3a , left side) so we de®ned its eects on the 7173 mut pCAT plasmid; the 0.2% activity seen was not dierent than the 0.3% activity seen with the empty pCMV5 plasmid (Figure 3a , right side). Transactivation by AML1B was eliminated by mutation of the AML1 site.
To de®ne additional amino acid regions required for transcriptional repression by TEL-AML1, we generated various internal or C terminal deletion mutant proteins, and performed additional transfection assays in MLA 144 cells, using the 7173 pCAT plasmid as a reporter construct. The TEL-AML1DRHD protein, which does not bind to the IL-3 promoter oligonucleotide in EMSA (shown in Figure 2b ), has no eect on IL-3 promoter activity (Figure 3b ). The TEL-AML1(290) mutant protein, which retains the Rhd but lacks the 180 C terminal amino acids presents in TEL-AML1 (and therefore lacks the NMTS and TAD), binds DNA and retains its ability to strongly repress the IL-3 promoter. However, deletion of an additional 74 amino acids from this protein, as in TEL-AML1(216), eliminates Repression of the IL-3 promoter by TEL-AML1 H Uchida et al its repressor activity (Figure 3b) , even though the TEL-AML1(216) protein still binds to the TGTGGT sequence in EMSA (Figure 2b ). Further deletion of AML1 amino acids, to 172, as in the TEL-AML1(172) mutant, eliminated its DNA binding activity (Figure 2b, lane 6 ). These data demonstrate that in addition to the Rhd, both the HLH domain and amino acids 216 ± 290 of AML1 are required for transcriptional repression by TEL-AML1. C-terminal deletion mutant analysis of the TEL-AML1DHLH protein demonstrated that in the absence of the HLH motif, the Rhd and amino acids 216 ± 290 are also required for activation of the 7173 IL-3 promoter construct by TEL-AML1DHLH (data not shown).
IL-3 is not expressed in t(12;21) positive ALL patient samples
Our experiments suggest that cells containing TEL-AML1 should not express IL-3. To con®rm this hypothesis, we examined whether autocrine production of IL-3 was found in freshly isolated ALL cells that express TEL-AML1 (Figure 4) . None of the 20 TEL-AML1 expressing ALL patient samples tested, by an RT ± PCR based assay, expressed IL-3 mRNA (®ve representative samples are shown in Figure 4a , lanes 2 ± 6), whereas IL-3 mRNA was easily detected in mRNA extracted from Con A-stimulated primary human T cells (Figure 4a, lane 7) . A similar RT ± PCR assay was performed to detect GM-CSF mRNA in these samples, and none were positive (data not shown). GAPDH control RT ± PCRs were performed to demonstrate the integrity of the RNA and the reverse transcription process (Figure 4b ). Samples processed without reverse transcriptase had no ampli®ed product (lane 1).
Discussion
The AML1 (CBFA2) and TEL (ETV6) genes are frequent targets of chromosomal translocations in human leukemia. Various portions of the AML1 protein are contained in the chimeric transcriptional regulators AML1/ETO, AML1/EV1-1, and TEL-AML1, and similarly N terminal or C terminal portions of TEL are found in the TEL-AML1, TEL-ABL, TEL-JAK2, TEL-EVI-1 and MN1-TEL fusion proteins. The critical cellular processes altered by the TEL-AML1 chimeric product cannot be easily understood based on the known biological activities of the wild type proteins or the known functions of these other chimeric proteins (Nucifora and Rowley, 1995) . Although AML1/ETO and AML1/EVI-1 can function as transcriptional repressors Frank et al., 1995; Tanaka et al., 1995) (290) repress the activity of the 7173 IL-3 pCAT reporter plasmid, whereas neither TEL-AML1DRhd nor TEL-AML1(216) aect its promoter activity. As in Figure 3a , the activity of the 7173 IL-3 CAT construct in the presence of the empty pCMV5 expression plasmid was assigned a value of 1.0. The bars show the standard error (n5four experiments) Figure 4 RT ± PCR analysis of primary TEL-AML1 positive ALL patient samples demonstrates no detectable IL-3 transcript. Ethidium bromide stained agarose gel show the PCR products generated using primer pairs for IL-3 mRNA (a) or for GAPDH mRNA (b). Lane 1; negative control, lanes 2 ± 6; patient samples, lane 7; positive control (ConA stimulated human T cells). The arrows in a and b indicate the location of the speci®c PCR products for IL-3, and GAPDH, respectively CSFR promoter) and AML1/EV1-can activate AP-1 activity (Mitani et al., 1994) . The transcriptional activities of AML1/ETO require the Rhd of AML1, and varying amino acids contributed by ETO (Klampfer et al., 1996; Lenny et al., 1995; Rhoades et al., 1996) whereas the activation of AP-1 activity by AML1/EVI-1 requires EVI-1 amino acids and not the Rhd (Mitani et al., 1994) . We, and others, have now demonstrated that AML1/ETO and TEL-AML1 act as repressors of basal transcription of the IL-3 promoter and TCR-b enhancer in T cell lines (Uchida et al., 1997) , or in C33a cervical carcinoma cells Meyers et al., 1995) , respectively. In contrast, repression of M-CSFR promoter activity by TEL-AML1 only occurred in the presence of C/EBPa (Fears et al., 1997) .
Thus far, the regulatory eects of TEL-AML1 have been delineated on the TCRa enhancer and the M-CSF receptor promoter, although altered expression of these genes would not be expected to be pathogenetically important in t(12;21) B cell ALL. In the present study, we investigated the transcriptional regulatory eect of TEL-AML1 on the human IL-3 promoter. We have shown that AML1B protein is converted from a transcriptional activator to a repressor in lymphoid cells, when fused to TEL. The mechanism of transcriptional repression by TEL-AML1 is unclear. Several fusion transcription factors that act as repressors (e.g. AML1/ETO, PLZF-RARa and PMLRARa have recently been shown to bind co-repressor molecules such as N-CoR or SMRT (He et al., 1998) . AML1/ETO apparently binds N-CoR via ETO amino acids, thus the repression of transcription by TEL-AML1 may not involve the same molecules.
The identi®cation of three distinct required domains in TEL-AML1, and the modular nature of transcription factors, suggests that amino acids in each domain may contact other proteins or may be post-transcriptionally modi®ed to alter transcriptional regulatory activity. Activities for these domains have been de®ned in other settings as well, allowing us to draw a schematic view of the interactions between TEL-AML1, DNA, and other proteins in the cell ( Figure   5 ). The transcriptional activating domain of AML1 has been shown to bind the p300 co-activator molecule, and it is possible that dimerization of TEL-AML1 by the HLH (pointed) domain prevents this interaction. The HLH domain of TEL, which mediates both the homodimerization of TEL-AML1 and its heterodimerization with TEL (McLean et al., 1996) , does not appear to determine the anity of TEL-AML1 for DNA, as its deletion from TEL-AML1 did not increase its anity for the TGTGGT sequence.
The Rhd in AML1B is required for DNA binding, and for heterodimer formation with CBFb, which augments its DNA binding anity and potentially increases its transactivating activity in the cell Rhoades et al., 1996) . The Rhd is also involved in the interaction of AML1 proteins with ets-1 (Wotton et al., 1994) and C/EBPa . The Rhd is essential for repression of the IL-3 promoter by TEL-AML1. In contrast, neither the nuclear matrix targeting signal (NMTS), which was recently localized to amino acids 351 ± 381 of AML1B (Zeng et al., 1997) , nor the transcriptional activation domain (TAD) are required for repression as these regions are absent from the TEL-AML1 (290) repressor. Although the NMTS region can specify the intracellular location of AML1B, it is not known whether this region also targets TEL-AML1 to the nuclear matrix.
The third domain required for repression by TEL-AML1 is located just C terminal to the Rhd, within amino acids 216 ± 290. This region of AML1 overlaps with the region of AML1B (amino acids 204 ± 314) that has been shown to bind the ALY protein, a 32 kDa context dependent transcriptional activator (Bruhn et al., 1997) . Intermolecular interactions of AML3 (CBFA1) with ALY increase the binding anity of AML3 for DNA, but deletion of the ALY binding region from TEL-AML1 does not appear to aect its in vitro DNA binding activity (compare TEL-AML1(216) with TEL-AML1(290) in Figure 2b ), although it could alter its in vivo DNA binding activity. Also located in the 216 ± 290aa region is serine 276 , which together with serine 293 , constitute two major sites of in vitro phosphorylation by ERK kinase (Tanaka et al., 1996) . Serine to alanine mutations had no eect on the DNA binding of the normal AML1b protein, but did reduce its transcriptional activating activity and its ability to stimulate the growth of NIH 3T3 cells in soft agar (Tanaka et al., 1996) . Deletion of serine 293 had no signi®cant aect on the DNA binding or repressor activity of TEL-AML1(290); the role of serine 276 was not speci®cally addressed by our studies. AML cells cultured in vitro often express hematopoietic growth factors, whereas autocrine growth factor production by fresh human leukemia cells is uncommon (Rogers et al., 1994) . Murine erythroleukemias and mast cell tumors often express IL-3 or GM-CSF, as do several human megakaryocytic cell lines, and certain oncogenes, including bcr-abl, can render cells growth factor independent without actually stimulating the expression of the requisite growth factor. The TEL-AML1 fusion is the most common molecular abnormality in childhood ALL, but its expression does not result in autocrine production of IL-3, as none of the 20 fresh TEL-AML1 positive B cell ALL samples expressed IL-3 mRNA (or GM-CSF). Thus, B cell Figure 5 Schematic model depicting the fusion of TEL amino acids with AML1B amino acids, the known functional domains contained in the fusion protein and the potential protein-protein interactions that could account for repression and activation of gene expression. Protein-protein interactions involving the rhd and ETS proteins, C/EBP, or CBFb are not shown ALL with a t(5;14) abnormality remains the only ALL identi®ed thus far that expresses IL-3 (Grimaldi and Meeker, 1989; Meeker et al., 1990) . Although IL-3 has been shown to have an inhibitory role on the growth of B cells under certain in vitro conditions (Yonemura et al., 1996) , we have no evidence that repression of IL-3 expression by TEL-AML1 in B cells could have functional consequences.
Although AML1 proteins are rather ubiquitously expressed, TEL-AML1 expressing leukemias are of B cell lineage, whereas AML1/ETO is expressed solely in myeloid lineage leukemias. Whether or not these fusion proteins assist in de®ning the lineage speci®city of their characteristic leukemia syndromes, or whether the particular AML1 fusion partner involved in each rearrangement is determined by its cellular or temporal expression pattern, remains to be determined.
Materials and methods

Plasmid construction and protein preparation
The TEL-AML1 protein consists of 796 amino acids ( Figure 1) ; its N terminal 336 amino acids are derived from TEL, and are fused to amino acids 21 ± 479 of AML1B (including the Rhd and putative transcriptional activation domain) (Golub et al., 1995) . cDNAs encoding TEL-AML1, and a mutant TEL-AML1 protein lacking the HLH domain, were subcloned into the pET-30b(+) expression vector (Novagen) in frame, and used to transform E. coli strain BL21(DE3) cells. Three terminal deletion mutants of the TEL-AML1 protein were created: TEL-AML1(290), TEL-AML1(216), and TEL-AML1(172), which contain AML1 amino acids 21 ± 290, 21 ± 216, or 21 ± 172, respectively. To generate the TEL-AML1(290), TEL-AML1(216) and TEL-AML1(172) mutant proteins, EcoRI ± BamHI, EcoRI ± SmaI, and EcoRI-Asp700I fragments of the TEL-AML1 cDNA were subcloned into the pET-30b(+) vector in frame, respectively, and used to transform BL21(DE3) cells. The pET-30b(+)/TEL-AML1DRHD plasmid was created by deleting the AvrIIBsu36 I fragment from the TEL-AML1 cDNA; the TEL-AML1DRHD protein lacks 40 amino acids in the Rhd.
Preparation of bacterially expressed TEL-AML1 proteins was performed according to the manufacturer's instructions (Novagen), as previously described (Uchida et al., 1997) . Bacterially expressed AML1A protein (the 250 amino acid isoform of AML1) and bacterially expressed AML1B protein (the 479 amino acid isoform of AML1) were also prepared as previously described (Uchida et al., 1997) . 1 mM PMSF, 10 mg/ml aprotinin, and 10 mg/ml leupeptin were added to avoid degradation of the proteins. The integrity of expressed proteins was con®rmed by SDS ± polyacrylamide gel electrophoresis followed by Coomassie blue staining, and an S-Tag Western blot protein detection system (Novagen). The amounts of TEL-AML1 protein in the various bacterial lysates used for the EMSAs were nearly identical, as shown by SDS ± PAGE. The expressed TEL-AML1 proteins were not further puri®ed, so the lysate from IPTG-induced BL21(DE3) cells transformed with the empty pET-30(+) plasmid (without the TEL-AML1 cDNAs), was used as the protein control for all experiments.
Electrophoretic mobility shift assays (EMSA) using bacterially expressed proteins
The following complementary single stranded oligonucleotides were synthesized and used in EMSAs.
The wild type AA' oligonucleotide contains IL-3 promoter sequences from nucleotides (nt) 7141 to 7128, 5'-GTC-TGTGGTTTTCT-3', whereas the mutant AA' oligonucleotide containing ®ve nucleotide substitutions in the AML1 site, 5'-GTCcagacTTTTCT-3'.
The wild type and mutant GM-CSF promoter oligonucleotides have been previously described (Frank et al., 1995) . The wild type oligonucleotide is 5'-TCCCTGGCA-TTTTGTGGTCACC-3', (labeled GM-CSF C.B.S.) and the mutant oligonucleotide, which lacks an intact AML1 binding site is 5'-TCCCTGGCATTTcagacTCACC-3' [labeled GM-CSF mut. (mutant)].
One strand of these oligonucleotides was annealed at 1008C for 3 min to its complementary oligonucleotide, and then labeled using T4 polynucleotide kinase and [g-32 P]ATP. 1 ng of probe was incubated with 1 ml of bacterial cell supernatant containing the expressed fusion protein for 25 min at room temperature in a 20 ml reaction containing 20 mM HEPES (pH 7.9), 0.5 mM EDTA, 2 mM DTT, 10% glycerol, 50 mM KCl, 1 mg poly dl:dC (Pharmacia), and unlabeled competitor. The molar excess of competitor is indicated in each ®gure legend. Following incubation, the samples were loaded onto a 4% polyacrylamide gel and run in 0.256TBE at room temperature. Gels were dried and exposed to XAR Kodak ®lm overnight, using intensifying screens at 7808C.
Cell culture and transient transfection assays
The MLA 144 gibbon ape T-cell leukemia line was cultured in Iscove's modi®ed Dulbecco's medium supplemented with 10% fetal bovine serum and 2 mM L-glutamine, 100 units/ ml of penicillin and 100 mg/ml of streptomycin. All cells were fed the day prior to transfection, and the transient transfections were performed using a previously published electroporation method (Cann et al., 1988) , and a BioRad Gene Pulser set at 250 volts and 960 mF. 5610 6 cells were transfected with 10 mg of a CMV promoter-based expression construct, containing either the AML1B cDNA, the TEL-AML1 cDNA, or the TEL-AML1DRHD, TEL-AML1(216), TEL-AML1(290), or TEL-AML1DHLH cDNA, or vector alone, and 10 mg of a 7173pCAT IL-3 promoter-CAT reporter construct, which contains 173 base pairs (bp) of IL-3 promoter sequences upstream of the major transcriptional start site linked to the CAT gene (Uchida et al., 1997; Wolin et al., 1993) . The consensus AML1 binding site in the IL-3 promoter, TGTGGT, is located between bp 7138 to 7133, and is therefore included in the 7173 IL-3 promoter CAT reporter plasmid. The 7173 mut pCAT reporter construct is identical to the 7173 pCAT plasmid, except the TGTGGT sequence was mutated to cagacT (Uchida et al., 1997) .
Forty eight hours after electroporation, cells were harvested, total cellular extracts were prepared, and CAT activity was measured using standard techniques (Seed and Sheen, 1988) . To correct for dierences in the transformation eciency, 5 mg of pCMV-Luciferase plasmid (kindly provided by Dr Andrew Zelenetz) was added to each transfection sample, and total cellular lysates obtained at the time of cell harvest, were assayed for luciferase activity according to manufacturer's instructions (Promega).
Detection of IL-3 mRNA by reverse transcription ± polymerase chain reaction (RT ± PCR)
Bone marrow samples were obtained from 20 patients with ALL following informed consent at St Jude Children's Research Hospital (JRD). Total RNA was prepared from light density mononuclear bone marrow cells using an acidi®ed guanidinium phenol chloroform method (Chomczynski and Sacchi, 1987) . cDNA was prepared using previously published methods (Miyazaki et al., 1996) . Brie¯y, 5 mg of total RNA was incubated with dNTP mix, random primer, RNasin, and MMLV-reverse transcriptase (Gibco/BRL), and 56RT buer for 60 min at 378C. Commercially available primers were used in the PCR reaction, to detect IL-3 (Yang et al., 1986) , or GM-CSF mRNA (Miyatake et al., 1985) . The PCR reactions were performed with 0.5 ml of cDNA, dNTP mix, 50 mM each of primers, 2.5 units of Taq polymerase (Promega), and 106Taq. buer (containing 1.5 mM of ®nal MgCl 2 concentration). Thirty cycles of PCR were performed as follows: denaturation at 948C for 1 min, annealing at 558C for 1 min, and extension at 728C for 1 min. The PCR products were electrophoresed on 1.5% agarose gel, and visualized under UV light with ethidium bromide staining.
